New Study Investigates the Economic Impact and Utility of Continuous Noninvasive Hemoglobin Measurement with Masimo SpHb® in Reducing Unnecessary Blood Transfusions
In the study, Dr. Ribed-Sánchez and colleagues at HM Hospitales,
ETSII-Universidad Nacional de Educaíon a Distancia (UNED), and
The researchers found a decrease in the percentage of patients receiving
a transfusion from 48.7% in the control group to 45.1% in the
experimental (SpHb) group, a 7.4% reduction. The number of units
transfused per patient dropped from 1.322 to 1.156, a 12.56% decrease.
Based on the average cost of a unit of blood in
The researchers concluded, “Constant monitoring of the value of hemoglobin during surgeries with significant blood loss significantly reduces blood transfusions. Based on the reduction of transfusions by using this measurement technology, health facilities can significantly reduce their costs while improving quality of care.”
SpHb is not intended to replace laboratory blood testing. Clinical decisions regarding red blood cell transfusions should be based on the clinician’s judgment considering among other factors: patient condition, continuous SpHb monitoring, and laboratory diagnostic tests using blood samples.
@MasimoInnovates | #Masimo
Ribed-Sánchez B, González-Gaya C, Varea-Díaz S, Corbacho-Fabregat C,
Pérez-Otoyza J, and
Belda-Iniesta C. Economic Analysis of the Reduction of Blood Transfusions during Surgical Procedures While Continuous Hemoglobin Monitoring is Used. Sensors. 2018, 18, 1367; doi:10.3390/s18051367.
- Ehrenfeld JM et al. Continuous Non-invasive Hemoglobin Monitoring during Orthopedia Surgery: A Randomized Trial. J Blood Disorders Transf. 2014. 5:9. 2.
Awada WN et al. Continuous and noninvasive hemoglobin monitoring
reduces red blood cell transfusion during neurosurgery: a prospective
cohort study. J
Clin Monit Comput. 2015 Feb 4.
Imaizumi et al. Continuous and noninvasive hemoglobin monitoring may
reduce excessive intraoperative
RBCtransfusion. Proceedings from the 16th World Congress of Anaesthesiologists, Hong Kong. Abstract #PR607.
Kamal A et al. The Value of Continuous Noninvasive Hemoglobin
Monitoring in Intraoperative Blood Transfusion Practice during
Abdominal Cancer Surgery.
Open Journal of Anesthesiology, 6, 13-19. DOI: 10.4236/ojanes.2016.63003
- Published clinical studies and abstracts on Masimo SpHb can be found at http://www.masimo.com/evidence/pulse-co-oximetry/sphb/.
Nathan N et al. Impact of Continuous Perioperative SpHb Monitoring.
Proceedings from the 2016 ASA Annual Meeting,
Chicago. Abstract #A1103.
ORi has not received
*The use of the trademark Patient SafetyNet is under license from
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;
- Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
- Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation.
The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
Masimodata on file.
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo SpHb®. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that
Evan Lamb, 949-396-3376